KDR and hepatocellular carcinoma: Sorafenib, a multiple TKI, as the only first-line systemic treatment of patients with advanced HCC for a long time, exerts antitumor effects by suppressing vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), Raf-1, and B-Raf (58).